U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07498426) titled 'A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy' on March 23.
Brief Summary: This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.
Study Start Date: May 29
Study Type: INTERVENTIONAL
Condition:
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Intervention:
OTHER: NIO752
Solution of antisense oligonucleotide.
DRUG: Placebo
Placebo solution
Recruitment Status: NOT_YET_RECR...